Safety of infliximab in patients suffering from inflammatory bowel disease.
C
C
Felley
P
P
Michetti
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000473:pathology; D005765:Gastrointestinal Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D018579:Patient Selection; D015203:Reproducibility of Results; D012307:Risk Factors; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab